- Home
- BWLP vs IMNM Comparison
BWLP vs IMNM Comparison
Compare BWLP & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BWLP | IMNM |
|---|---|---|
| Founded | 1935 | 2006 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.2B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | BWLP | IMNM |
|---|---|---|
| Price | $16.34 | $24.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $31.22 |
| AVG Volume (30 Days) | 415.8K | ★ 1.9M |
| Earning Date | 02-26-2026 | 03-18-2026 |
| Dividend Yield | ★ 8.01% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $3,693,482,000.00 | $9,679,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.16 | $11.53 |
| P/E Ratio | $14.67 | ★ N/A |
| Revenue Growth | ★ 2.54 | N/A |
| 52 Week Low | $7.86 | $5.15 |
| 52 Week High | $16.68 | $27.65 |
Technical Indicators
Market Signals| Indicator | BWLP | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 71.51 | 55.62 |
| Support Level | $15.58 | $24.03 |
| Resistance Level | $16.68 | $27.65 |
| Average True Range (ATR) | 0.42 | 1.46 |
| MACD | 0.10 | -0.21 |
| Stochastic Oscillator | 88.52 | 31.66 |
Price Performance
Historical ComparisonAbout BWLP BW LPG Limited
BW LPG Ltd is an LPG shipping. It uses pioneering technology to power its vessels with cleaner-burning liquefied petroleum gas (LPG) and invest in R&D to take towards a zero-carbon future. The company is organized into two main segments: The shipping segment and the product services segment which buy and sell liquid petroleum gas and deliver it to customers. It generates the majority of its revenue from the shipping segment.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.